06 April 2017 at 12:24 GMT
Looking at charts for biotech firm Genmab, we see a great many ominous indicators pointing to an abrupt reversal from this stock's multi-month ascent.
Read the article
Trade view / 11 November 2015 at 14:15 GMT
Our Genmab short trade has hit its stop-loss and as a result we are booking a 14.3% loss on the position.
Read the Trade View
19 May 2014 at 18:12 GMT
GlaxoSmithKline and Genmab did not meet primary endpoint with Ofatumumab and are unlikely to move forward with filing
Read the Squawk